T cell coinhibition in prostate cancer

New immune evasion pathways and emerging therapeutics

Yael S. Barach, Jun Sik Lee, Xingxing Zang

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

T cell-mediated adaptive immune response is controlled by both positive costimulation and negative coinhibition, generated mainly by the interaction between the B7 family and their receptor CD28 family. Coinhibition is exploited by prostate cancer as an immune evasion pathway. Overexpression of coinhibitory B7x and B7-H3 in prostate cancer correlates with poor disease outcome, whereas tumor-infiltrating immune cells have enhanced expression of PD-L1 and its receptor PD-1. New insights into the complex mechanisms governing B7 expression in the tumor microenvironment have been reported and therapies aimed at overcoming T cell coinhibition with antagonistic monoclonal antibodies are emerging as effective tumor immunotherapies. Therapies that block B7x and B7-H3, either as monotherapies or in synergism with traditional therapies, should be pursued.

Original languageEnglish (US)
Pages (from-to)47-55
Number of pages9
JournalTrends in Molecular Medicine
Volume17
Issue number1
DOIs
StatePublished - Jan 2011

Fingerprint

Immune Evasion
Prostatic Neoplasms
T-Lymphocytes
Programmed Cell Death 1 Receptor
Tumor Microenvironment
Adaptive Immunity
Immunotherapy
Neoplasms
Therapeutics
Monoclonal Antibodies

ASJC Scopus subject areas

  • Molecular Biology
  • Molecular Medicine
  • Medicine(all)

Cite this

T cell coinhibition in prostate cancer : New immune evasion pathways and emerging therapeutics. / Barach, Yael S.; Lee, Jun Sik; Zang, Xingxing.

In: Trends in Molecular Medicine, Vol. 17, No. 1, 01.2011, p. 47-55.

Research output: Contribution to journalArticle

@article{c1bc2d1216964082805ab3f5e6d110be,
title = "T cell coinhibition in prostate cancer: New immune evasion pathways and emerging therapeutics",
abstract = "T cell-mediated adaptive immune response is controlled by both positive costimulation and negative coinhibition, generated mainly by the interaction between the B7 family and their receptor CD28 family. Coinhibition is exploited by prostate cancer as an immune evasion pathway. Overexpression of coinhibitory B7x and B7-H3 in prostate cancer correlates with poor disease outcome, whereas tumor-infiltrating immune cells have enhanced expression of PD-L1 and its receptor PD-1. New insights into the complex mechanisms governing B7 expression in the tumor microenvironment have been reported and therapies aimed at overcoming T cell coinhibition with antagonistic monoclonal antibodies are emerging as effective tumor immunotherapies. Therapies that block B7x and B7-H3, either as monotherapies or in synergism with traditional therapies, should be pursued.",
author = "Barach, {Yael S.} and Lee, {Jun Sik} and Xingxing Zang",
year = "2011",
month = "1",
doi = "10.1016/j.molmed.2010.09.006",
language = "English (US)",
volume = "17",
pages = "47--55",
journal = "Trends in Molecular Medicine",
issn = "1471-4914",
publisher = "Elsevier Limited",
number = "1",

}

TY - JOUR

T1 - T cell coinhibition in prostate cancer

T2 - New immune evasion pathways and emerging therapeutics

AU - Barach, Yael S.

AU - Lee, Jun Sik

AU - Zang, Xingxing

PY - 2011/1

Y1 - 2011/1

N2 - T cell-mediated adaptive immune response is controlled by both positive costimulation and negative coinhibition, generated mainly by the interaction between the B7 family and their receptor CD28 family. Coinhibition is exploited by prostate cancer as an immune evasion pathway. Overexpression of coinhibitory B7x and B7-H3 in prostate cancer correlates with poor disease outcome, whereas tumor-infiltrating immune cells have enhanced expression of PD-L1 and its receptor PD-1. New insights into the complex mechanisms governing B7 expression in the tumor microenvironment have been reported and therapies aimed at overcoming T cell coinhibition with antagonistic monoclonal antibodies are emerging as effective tumor immunotherapies. Therapies that block B7x and B7-H3, either as monotherapies or in synergism with traditional therapies, should be pursued.

AB - T cell-mediated adaptive immune response is controlled by both positive costimulation and negative coinhibition, generated mainly by the interaction between the B7 family and their receptor CD28 family. Coinhibition is exploited by prostate cancer as an immune evasion pathway. Overexpression of coinhibitory B7x and B7-H3 in prostate cancer correlates with poor disease outcome, whereas tumor-infiltrating immune cells have enhanced expression of PD-L1 and its receptor PD-1. New insights into the complex mechanisms governing B7 expression in the tumor microenvironment have been reported and therapies aimed at overcoming T cell coinhibition with antagonistic monoclonal antibodies are emerging as effective tumor immunotherapies. Therapies that block B7x and B7-H3, either as monotherapies or in synergism with traditional therapies, should be pursued.

UR - http://www.scopus.com/inward/record.url?scp=78650997385&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78650997385&partnerID=8YFLogxK

U2 - 10.1016/j.molmed.2010.09.006

DO - 10.1016/j.molmed.2010.09.006

M3 - Article

VL - 17

SP - 47

EP - 55

JO - Trends in Molecular Medicine

JF - Trends in Molecular Medicine

SN - 1471-4914

IS - 1

ER -